41 Quotes by Jan Wald

The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.

One thing the company loses by not being part of J&J is not having more money for market development education and training

My sense is J&J is going to have to acquire to get a growth rate that investors will think is respectable.

I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.

But that is an awfully long time to look out for pharmaceuticals.

I have a feeling that Temecula is pretty safe.

I don't think it's a sure thing by any stretch, but I think they have a good chance of making it.

I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.

It appears that a good portion of doctors are willing to give Guidant a fresh look in their practices, and perhaps faster than most believed.